Pressurized intraperitoneal aerosol chemotherapy for recurrent ovarian, fallopian or primary peritoneal cancer with peritoneal carcinomatosis: a narrative review
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, Soohyun | - |
dc.contributor.author | Paik, Haerin | - |
dc.contributor.author | Park, Soo Jin | - |
dc.contributor.author | Lee, Eun Ji | - |
dc.contributor.author | Kim, Hee Seung | - |
dc.date.accessioned | 2024-06-13T06:00:32Z | - |
dc.date.available | 2024-06-13T06:00:32Z | - |
dc.date.issued | 2021-03 | - |
dc.identifier.issn | 2227-684X | - |
dc.identifier.issn | 2227-8575 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/74155 | - |
dc.description.abstract | For recurrent ovarian, fallopian or primary peritoneal cancer with peritoneal carcinomatosis (PC), it is challenging to resect tumors completely or to get complete remission by intravenous (IV) chemotherapy, and many patients show the resistance to various chemotherapeutic agents for IV chemotherapy ultimately. As an alternative, pressurized intraperitoneal aerosol chemotherapy ( PIPAC) has been introduced for treating the disease, which delivers chemotherapeutic agents as an aerosol form while maintaining high intraperitoneal (IP) pressure. Based on preclinical studies, PIPAC showed better penetration depth and distribution of drugs into the peritoneum in comparison to conventional IP chemotherapy. Tumor regression on histology and peritoneal carcinomatosis index (PCI) has also been shown in relevant studies. In addition, most of the PIPAC procedures were completed successfully with acceptable toxicity due to the use of a low dose of chemotherapeutic agents. For considering these advantages of PIPAC, we review the current status of PIPAC for treating recurrent ovarian, fallopian or primary peritoneal cancer through literature review. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | AME PUBLISHING COMPANY | - |
dc.title | Pressurized intraperitoneal aerosol chemotherapy for recurrent ovarian, fallopian or primary peritoneal cancer with peritoneal carcinomatosis: a narrative review | - |
dc.type | Article | - |
dc.identifier.doi | 10.21037/gs-2019-ursoc-12 | - |
dc.identifier.bibliographicCitation | GLAND SURGERY, v.10, no.3, pp 1244 - 1251 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000635261400042 | - |
dc.identifier.scopusid | 2-s2.0-85103474798 | - |
dc.citation.endPage | 1251 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 1244 | - |
dc.citation.title | GLAND SURGERY | - |
dc.citation.volume | 10 | - |
dc.type.docType | Review | - |
dc.publisher.location | 중국 | - |
dc.subject.keywordAuthor | Pressurized | - |
dc.subject.keywordAuthor | intraperitoneal (IP) | - |
dc.subject.keywordAuthor | aerosol | - |
dc.subject.keywordAuthor | chemotherapy | - |
dc.subject.keywordAuthor | ovarian | - |
dc.subject.keywordAuthor | fallopian | - |
dc.subject.keywordAuthor | peritoneal | - |
dc.subject.keywordAuthor | cancer | - |
dc.relation.journalResearchArea | Surgery | - |
dc.relation.journalWebOfScienceCategory | Surgery | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.